CAS 74150-27-9: Pimobendan

Pimobendan CRS

Applications Pimobendan-d3, is the labeled analogue of Pimobendan (P447500), a cardiotonic agent. References Yokota, S. et al.: Yakuri Chiryo, 20, 1143 (1992); Yamamoto, M. et al.: Kank. Igaku Ken. Nenpo, 47, 155 (1996); Matsumoto, A. et al.: Cardiovas. Drugs Ther., 12, 595 (1998);

Pimobendan

Drugs with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoi

6-(2-(4-Methoxyphenyl)-1H-Benzo[D]Imidazol-5-Yl)-5-Methyl-4,5-Dihydropyridazin-3(2H)-One

Pimobendan

Pimobendan (UD-CG 115 BS) is a selective inhibitor of PDE3 (IC50: 0.32 μM).

Applications Pimobendan is a cardiotonic agent. The study of the cardiotonic mechanism of Pimobendan using ventricular muscles from rabbits and guinea pigs suggests that Pimobendan acts by inhibiting phosphodiesterase III and potassium channel. The potent venodilating action of Pimobendan makes it a suitable treatment option for patients with congestive heart failure (CHF) as it also improves systemic vasoconstriction. References Yokota, S. et al.: Yakuri Chiryo, 20, 1143 (1992); Yamamoto, M. et al.: Kank. Igaku Ken. Nenpo, 47, 155 (1996); Matsumoto, A. et al.: Cardiovas. Drugs Ther., 12, 595 (1998);

Pimobendan is a drug that has been shown to have positive effects on the cardiac function of experimental animals. It is a selective inhibitor of the enzyme phosphodiesterase 3 in cardiac tissues. Pimobendan also has effects on blood pressure, as it increases systolic pressure and decreases diastolic pressure. The pharmacokinetic properties of pimobendan are characterized by a concentration-time curve with a long terminal half-life. Pimobendan is also an ATP-sensitive K+ channel blocker, which causes increased intracellular K+ concentrations in the myocardium. This leads to an increase in cardiac contractility and relaxation, with an improvement in cardiac performance. Chronic oral administration of pimobendan has been shown to be effective in improving the long-term efficacy of treatment for congestive heart failure due to chronic valvular disease or dilated cardiomyopathy.